BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,045 filers reported holding BAXTER INTL INC in Q4 2017. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $703,000 | +53.2% | 8,163 | +44.5% | 0.26% | -30.6% |
| Q1 2020 | $459,000 | -18.3% | 5,651 | -16.0% | 0.37% | -13.5% |
| Q4 2019 | $562,000 | -8.3% | 6,725 | -4.1% | 0.43% | +20.8% |
| Q3 2019 | $613,000 | +1.3% | 7,012 | -5.1% | 0.36% | +5.0% |
| Q2 2019 | $605,000 | -12.8% | 7,385 | -13.5% | 0.34% | -22.8% |
| Q1 2019 | $694,000 | +19.7% | 8,539 | -3.2% | 0.44% | -7.0% |
| Q4 2018 | $580,000 | -32.8% | 8,817 | -21.2% | 0.47% | -19.0% |
| Q3 2018 | $863,000 | +44.6% | 11,192 | +38.5% | 0.58% | +53.4% |
| Q2 2018 | $597,000 | -63.5% | 8,080 | -67.9% | 0.38% | -65.4% |
| Q1 2018 | $1,636,000 | -19.6% | 25,153 | -20.1% | 1.10% | +30.9% |
| Q4 2017 | $2,034,000 | – | 31,468 | – | 0.84% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
| THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
| SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
| Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
| 13D Management LLC | 194,807 | $11,794,000 | 4.18% |
| Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
| Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
| ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
| Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
| PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |